Emilee R Wilhelm-Leen1, Wolfgang C Winkelmayer2. 1. Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA. 2. Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA; Section of Nephrology, Baylor College of Medicine, Houston, TX. Electronic address: winkelma@bcm.edu.
Abstract
BACKGROUND: Epoetin alfa (EPO) and darbepoetin alfa (DPO) are erythropoiesis-stimulating agents that are widely and interchangeably used for the treatment of anemia in patients with advanced chronic kidney disease and end-stage renal disease. No study has specifically compared the risks of hard study outcomes between EPO and DPO, including mortality. STUDY DESIGN: Systematic review of the literature and meta-analysis. SETTING & POPULATION: Patients enrolled in randomized trials comparing EPO versus DPO for the treatment of anemia in adults with chronic kidney disease, including those requiring dialysis. SELECTION CRITERIA FOR STUDIES: We conducted a systematic search of the literature (PubMed, CENTRAL, SCOPUS, and EMBASE, all years) and industry resources, using predefined search terms and data abstraction tools. We then summarized key characteristics and findings of these trials and performed a random-effects meta-analysis of trials with at least 3 months' duration to identify the summary OR of mortality between patients randomly assigned to DPO versus EPO. INTERVENTION: DPO versus EPO. OUTCOME: All-cause mortality. RESULTS: We identified 9 trials that met the stated inclusion criteria. Overall, 2,024 patients were included in the meta-analysis, of whom 126 died during follow-up, which ranged from 20 to 52 weeks. We found no significant difference in mortality between patients randomly assigned to DPO versus EPO (OR, 1.33; 95% CI, 0.88-2.01). No treatment heterogeneity across studies was detected (Q statistic=4.60; P=0.8). LIMITATIONS: Generalizability to nontrial populations is uncertain. CONCLUSIONS: Few trials directly comparing DPO and EPO have been conducted and follow-up was limited. In aggregate, no effect of specific erythropoiesis-stimulating agent on mortality was identified, but the confidence limits were wide and remained compatible with considerable harm from DPO. Absent adequately powered randomized trials, observational postmarketing comparative effectiveness studies comparing these erythropoiesis-stimulating agents are required to better characterize the long-term safety profiles of these agents.
BACKGROUND:Epoetinalfa (EPO) and darbepoetin alfa (DPO) are erythropoiesis-stimulating agents that are widely and interchangeably used for the treatment of anemia in patients with advanced chronic kidney disease and end-stage renal disease. No study has specifically compared the risks of hard study outcomes between EPO and DPO, including mortality. STUDY DESIGN: Systematic review of the literature and meta-analysis. SETTING & POPULATION: Patients enrolled in randomized trials comparing EPO versus DPO for the treatment of anemia in adults with chronic kidney disease, including those requiring dialysis. SELECTION CRITERIA FOR STUDIES: We conducted a systematic search of the literature (PubMed, CENTRAL, SCOPUS, and EMBASE, all years) and industry resources, using predefined search terms and data abstraction tools. We then summarized key characteristics and findings of these trials and performed a random-effects meta-analysis of trials with at least 3 months' duration to identify the summary OR of mortality between patients randomly assigned to DPO versus EPO. INTERVENTION: DPO versus EPO. OUTCOME: All-cause mortality. RESULTS: We identified 9 trials that met the stated inclusion criteria. Overall, 2,024 patients were included in the meta-analysis, of whom 126 died during follow-up, which ranged from 20 to 52 weeks. We found no significant difference in mortality between patients randomly assigned to DPO versus EPO (OR, 1.33; 95% CI, 0.88-2.01). No treatment heterogeneity across studies was detected (Q statistic=4.60; P=0.8). LIMITATIONS: Generalizability to nontrial populations is uncertain. CONCLUSIONS: Few trials directly comparing DPO and EPO have been conducted and follow-up was limited. In aggregate, no effect of specific erythropoiesis-stimulating agent on mortality was identified, but the confidence limits were wide and remained compatible with considerable harm from DPO. Absent adequately powered randomized trials, observational postmarketing comparative effectiveness studies comparing these erythropoiesis-stimulating agents are required to better characterize the long-term safety profiles of these agents.
Authors: T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner Journal: Circ Res Date: 1999-08-06 Impact factor: 17.367
Authors: Yves Vanrenterghem; Peter Bárány; Johannes F E Mann; Peter G Kerr; Janet Wilson; Nigel F Baker; Stephen J Gray Journal: Kidney Int Date: 2002-12 Impact factor: 10.612
Authors: Marcel Leist; Pietro Ghezzi; Giovanni Grasso; Roberto Bianchi; Pia Villa; Maddalena Fratelli; Costanza Savino; Marina Bianchi; Jacob Nielsen; Jens Gerwien; Pekka Kallunki; Anna Kirstine Larsen; Lone Helboe; Søren Christensen; Lars O Pedersen; Mette Nielsen; Lars Torup; Thomas Sager; Alessandra Sfacteria; Serhat Erbayraktar; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Carla Cerami-Hand; Qiao-Wen Xie; Thomas Coleman; Anthony Cerami; Michael Brines Journal: Science Date: 2004-07-09 Impact factor: 47.728
Authors: José M Portolés; Angel L M de Francisco; José L Górriz; Alberto Martínez-Castelao; Juan M López-Gómez; Manuel Arias; Juan J de la Cruz; Aleix Cases; Evaristo Fernández; Pedro Aljama Journal: Kidney Int Suppl Date: 2008-12 Impact factor: 10.545
Authors: Wolfgang C Winkelmayer; Tara I Chang; Aya A Mitani; Emilee R Wilhelm-Leen; Victoria Ding; Glenn M Chertow; M Alan Brookhart; Benjamin A Goldstein Journal: Am J Kidney Dis Date: 2015-05-02 Impact factor: 8.860
Authors: James B Wetmore; Suying Li; Heng Yan; Hairong Xu; Yi Peng; Marvin V Sinsakul; Jiannong Liu; David T Gilbertson Journal: PLoS One Date: 2018-09-26 Impact factor: 3.240
Authors: Peter Valent; Guntram Büsche; Igor Theurl; Iris Z Uras; Ulrich Germing; Reinhard Stauder; Karl Sotlar; Wolfgang Füreder; Peter Bettelheim; Michael Pfeilstöcker; Rainer Oberbauer; Wolfgang R Sperr; Klaus Geissler; Jürg Schwaller; Richard Moriggl; Marie C Béné; Ulrich Jäger; Hans-Peter Horny; Olivier Hermine Journal: Haematologica Date: 2018-08-03 Impact factor: 9.941